Stifel Financial Corp Has $1.16 Million Position in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE)

Stifel Financial Corp decreased its position in shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) by 4.0% in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 20,961 shares of the biopharmaceutical company’s stock after selling 866 shares during the period. Stifel Financial Corp’s holdings in Ultragenyx Pharmaceutical were worth $1,164,000 at the end of the most recent reporting period.

A number of other hedge funds have also recently added to or reduced their stakes in RARE. nVerses Capital LLC acquired a new position in Ultragenyx Pharmaceutical during the 2nd quarter worth $33,000. UMB Bank n.a. raised its position in Ultragenyx Pharmaceutical by 58.1% in the 2nd quarter. UMB Bank n.a. now owns 958 shares of the biopharmaceutical company’s stock worth $39,000 after purchasing an additional 352 shares during the last quarter. True Wealth Design LLC bought a new position in Ultragenyx Pharmaceutical in the third quarter valued at about $43,000. Values First Advisors Inc. bought a new stake in shares of Ultragenyx Pharmaceutical during the third quarter worth approximately $56,000. Finally, Capital Performance Advisors LLP bought a new stake in shares of Ultragenyx Pharmaceutical during the 3rd quarter valued at $107,000. Institutional investors and hedge funds own 97.67% of the company’s stock.

Insider Buying and Selling

In other news, CEO Emil D. Kakkis sold 8,273 shares of Ultragenyx Pharmaceutical stock in a transaction on Tuesday, December 10th. The shares were sold at an average price of $50.00, for a total transaction of $413,650.00. Following the transaction, the chief executive officer now owns 2,195,712 shares in the company, valued at $109,785,600. This trade represents a 0.38 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, CFO Howard Horn sold 7,465 shares of the company’s stock in a transaction dated Thursday, October 10th. The stock was sold at an average price of $52.76, for a total value of $393,853.40. Following the completion of the sale, the chief financial officer now owns 92,301 shares of the company’s stock, valued at approximately $4,869,800.76. The trade was a 7.48 % decrease in their position. The disclosure for this sale can be found here. 5.80% of the stock is owned by corporate insiders.

Ultragenyx Pharmaceutical Price Performance

Shares of NASDAQ:RARE opened at $44.22 on Monday. The company’s fifty day moving average price is $49.53 and its 200-day moving average price is $49.36. Ultragenyx Pharmaceutical Inc. has a one year low of $37.02 and a one year high of $60.37. The firm has a market capitalization of $4.08 billion, a price-to-earnings ratio of -6.83 and a beta of 0.56.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last announced its quarterly earnings results on Tuesday, November 5th. The biopharmaceutical company reported ($1.40) earnings per share for the quarter, beating the consensus estimate of ($1.45) by $0.05. Ultragenyx Pharmaceutical had a negative net margin of 106.93% and a negative return on equity of 187.12%. The business had revenue of $139.49 million during the quarter, compared to analysts’ expectations of $135.28 million. During the same quarter in the prior year, the company posted ($2.23) EPS. The firm’s revenue for the quarter was up 42.3% compared to the same quarter last year. As a group, equities research analysts expect that Ultragenyx Pharmaceutical Inc. will post -6.2 EPS for the current year.

Analyst Upgrades and Downgrades

Several equities analysts have recently weighed in on the company. Royal Bank of Canada reiterated an “outperform” rating and set a $77.00 price objective on shares of Ultragenyx Pharmaceutical in a report on Wednesday, November 6th. JPMorgan Chase & Co. dropped their target price on shares of Ultragenyx Pharmaceutical from $105.00 to $102.00 and set an “overweight” rating on the stock in a report on Thursday, November 21st. Cantor Fitzgerald reiterated an “overweight” rating and issued a $116.00 price objective on shares of Ultragenyx Pharmaceutical in a report on Wednesday, November 6th. Wells Fargo & Company increased their target price on Ultragenyx Pharmaceutical from $75.00 to $88.00 and gave the stock an “overweight” rating in a research note on Friday. Finally, TD Cowen boosted their price objective on shares of Ultragenyx Pharmaceutical from $61.00 to $73.00 and gave the company a “buy” rating in a report on Monday, October 21st. One investment analyst has rated the stock with a hold rating and twelve have issued a buy rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $88.46.

Ultragenyx Pharmaceutical Profile

Ultragenyx Pharmaceutical Inc, a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia.